Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.